NCT04163575View on ClinicalTrials.gov

Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

July 1, 2021

Study Completion Date

July 1, 2022

Conditions
LeukemiaLymphoma
Interventions
BIOLOGICAL

:Anti-CD22-CAR

Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)

Sponsors
All Listed Sponsors
collaborator

Hebei Yanda Ludaopei Hospital

OTHER

lead

Kecellitics Biotech Company Ltd

INDUSTRY

NCT04163575 - Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL | Biotech Hunter | Biotech Hunter